Disease · MONDO_0007191

Behcet disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Behcet disease. Diseases, record MONDO_0007191. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007191

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Behcet disease; Open Targets
Open Targets ID: MONDO_0007191; Open Targets
Other names: Adamantiades-Behcet disease, BEHCET DIS, Bechet syndrome, Behcet syndrome, Behcet's disease, Behcet's syndrome, Behcets Syndrome, Behet's syndrome (disorder), Behçet disease, Behçet syndrome, Behçet's syndrome, Behçet-Adamantiades syndrome, Morbus Behçet's syndrome, Triple-Symptom Complex, silk road disease; Open Targets
Disease Ontology: DOID:13241; Disease Ontology
MeSH: D001528; MeSH
NCI Thesaurus: C34416; NCI Thesaurus
Orphanet: ORPHA:117; Orphanet
Highest stage of its drugs: Approval, for 2 of its 40 drugs, from EMA Human Drugs and TTD; Open Targets

Drugs40

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
APREMILAST	CHEMBL514800	Small molecule	Approval	EMA Human Drugs	5	2	2	Drugs and targets
EZOGABINE	CHEMBL41355	Small molecule	Approval	TTD	1	0	0	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MUFEMILAST	CHEMBL5095240	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
RIVAROXABAN	CHEMBL198362	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SECUKINUMAB	CHEMBL1743068	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 40

See all 40 drugs

Targets70

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	3	Interferon alpha/beta receptor agonist	Phase 3	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	3	Interferon alpha/beta receptor agonist	Phase 3	https://conductscience.org/library/genes/3455	Drugs and targets
TNF	Tumor necrosis factor	3	TNF-alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7124	Drugs and targets
IL1B	Interleukin-1 beta	2	Interleukin-1 beta inhibitor; Interleukin-1 beta negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/3553	Drugs and targets
IL2RA	Interleukin-2 receptor	2	Interleukin-2 receptor agonist; Interleukin-2 receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3559	Drugs and targets
IL2RB	Interleukin-2 receptor	2	Interleukin-2 receptor agonist; Interleukin-2 receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3560	Drugs and targets
IL2RG	Interleukin-2 receptor	2	Interleukin-2 receptor agonist; Interleukin-2 receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3561	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	2	Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Tyrosine-protein kinase JAK2	2	Tyrosine-protein kinase JAK2 inhibitor	Phase 2	https://conductscience.org/library/genes/3717	Drugs and targets

1 to 10 of 70

See all 70 targets

Trials31

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02307513	A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease	Phase 3	207	2019-09-11	Behçet's Syndrome	APREMILAST	Its record names the disease	ClinicalTrials.gov
NCT00995709	Phase III Study in Refractory Behcet's Disease	Phase 3	118	2015-08-31	Behcet Disease	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT00866359	A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease	Phase 2	111	2014-08-27	Behcet Syndrome	APREMILAST	Its record names the disease	ClinicalTrials.gov
NCT01093846	38 Week Extension Study to CAIN457C2303	Phase 3	59	2016-02-22	Uveitis	SECUKINUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02756650	1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement	Phase 2	8	2020-06-11	Behcet Disease	CANAKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT01441076	Anakinra for Behcet s Disease	Phase 1/2	6	2017-05-12	Autoimmune Connective Tissue Disorder, Immune System Diseases	ANAKINRA	Its record names the disease	ClinicalTrials.gov
NCT01693653	Tocilizumab for the Treatment of Behcet's Syndrome	Phase 2	1	2016-06-02	Behcet Syndrome	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00700297	Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease	Phase 2	169		Behcet's Syndrome	COLCHICINE	Its record names the disease	ClinicalTrials.gov
NCT06145893	A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease	Phase 3	162		Behçet's Disease	MUFEMILAST	Open Targets' reading of its record	ClinicalTrials.gov
NCT06780462	Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome	Phase 3	134		Behcet Syndrome	RIVAROXABAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 31

See all 31 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38782788	RESULT	1	PubMed
34864108	RESULT	1	PubMed
29471416	RESULT	1	PubMed
28528519	RESULT	1	PubMed
41748391	DERIVED	1	PubMed
41400947	DERIVED	1	PubMed
39915014	DERIVED	1	PubMed
37316690	DERIVED	2	PubMed
35798511	DERIVED	1	PubMed
31722152	DERIVED	1	PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007191

GET https://conductscience.org/api/diseases/v1/MONDO_0007191/drugs?page=2

API reference For AI assistants